Central Composite Designed Taste Masked Ion Exchange Resinates for Development of Azithromycin Dispersible Tablets

Abstract

ABTRSACT Purpose:The purpose of the present investigation was to formulate taste masked dispersible tablets of azithromycin using complexation by ion exchange resin applying the central composite design. Methodology:The basic methodology behind the present work was the application of ion exchange resin complexation for masking the bitter taste of azithromycin. The central composite design (CCD) was applied to study the effect of two critical factors i.e. swelling time (X ) and stirring time (X ) on percent drug 1 2 complexed and cumulative percentage drug release. ANOVA was applied to percent drug complexed and cumulative percentage drug release to study the tting and the signicance of the model. The drug resinate was nally formulated into dispersible tablets by direct compression method. Findings:The drug resin ratio of 1:3 and pH 6 were found to have maximum drug loading onto the resin (Tulsion 335). The maximum drug release was found at high values of swelling and stirring time. The techniques of differential scanning calorimetry (DSC), X-ray diffraction (XRD) and Fourier transform infrared spectroscopy (FTIR) clearly indicated the formation of drug resin complex. Further, the formulated tablets were found to be within the pharmacopoeial limits. Originality:The present work is a novel attempt to prepare optimized taste masked formulation of extremely bitter drug azithromycin to overcome the problem of swallowing conventional tablets in case of paediatric patients. Conclusion:The technique of ion exchange resin complexation was successfully applied to prepare the taste masked azithromycin dispersible tablets. Data revealed that the developed dispersible tablets showed better taste prole when compared with the marketed formulation and were found to be stable.

AripiprazoleMontmorillonite: A New Organic–Inorganic Nanohybrid Material for Biomedical Applications

“…Recent studies have reported that more than a half of the interviewed patients with schizophrenia (n = 400) preferred orally disintegrating tablets (ODT) to other dosage forms, such as tablets, for swallowing or oral delivery. [5][6][7] In this sense, other forms of delivery, such as the use of chewable or dissolvable tablets, [8][9][10] or rapidly dissolving films, [11][12][13] could be advantageous; however, these forms must be preceded by the development of taste-masking formulations, owing to the unpleasant taste of APZ. Numerous approaches have been employed in the field of taste masking, most of which were have been based on the encapsulation of drugs inside polymeric materials, such as hydroxypropylmethylcellulose (HPMC), Eudragit EPO, and Abstract: Poor aqueous solubility and the unpleasant taste of aripiprazole (APZ) have been recurring problems, owing to its low bioavailability and low patient tolerance, respectively.…”

“…In this manner, the nanohybrids could be the base formulation for ODTs, which are the most favoured form of oral delivery by schizophrenia patients. [5][6][7] To accomplish taste masking, the release of the drug from the nanohybrids at the buccal cavity should be greatly suppressed. On the contrary, for enhanced drug bio-A C H T U N G T R E N N U N G availability, the release of the drug from the nanohybrids should be rapid and efficient, at least comparable to other commercially available medication, Abilify , through the gastrointestinal (GI) tract.…”

Development of Binary and Ternary Complex of Cefuroxime Axetil With Cyclodextrin for Improving Pharmaceutical Characteristics

“…Slow discharge of the drug results into taste-masking due to drug is present in minimal and below the bitterness threshold in the oral cavity. In this analysis, the drug is analyzed from the dissolution media of phosphate buffer (pH 6.8) at concentrations below its bitterness threshold [43][44][45][46][47]. Threshold bitterness concentration is the lowest concentration that had a bitter taste.…”